Adjusted EPS from continuing operations in third-quarter 2017 was $0.91 compared to $1.01 in third-quarter 2016.ĭuring third-quarter 2017, the U.S. This decrease included the impact of an increase to interest expense, mainly due to the refinancing of the Company's secured debt in April 2017, and adjusted tax expense. GAAP net loss per share from continuing operations for third-quarter 2017 was $0.45, compared to diluted GAAP loss per share from continuing operations of $0.86 in third-quarter 2016.Īdjusted income from continuing operations in third-quarter 2017 was $204 million compared to $226 million in third-quarter 2016. This decrease included the impact of lower amortization of intangible assets in third-quarter 2017 and higher third-quarter 2016 tax expense primarily due to the amortization of a deferred charge. GAAP net loss from continuing operations in third-quarter 2017 was $100 million compared to GAAP net loss from continuing operations of $191 million during the same period in 2016. Generics Base business, generic competition adversely impacting the Branded Established Products portfolio and the ceasing of shipments of OPANA ® ER to customers by September 1, 2017. Generic Pharmaceuticals product discontinuances, pricing pressure from increased competition primarily impacting the U.S. The decline was primarily due to previously announced U.S. Total revenues decreased by 11 percent to $787 million in third-quarter 2017 compared to the same period in 2016. In the case of Adjusted Diluted Weighted Average Shares, Adjusted Income from Continuing Operations is used in determining whether to include such dilutive impact. (1) Diluted per share data is computed based on weighted average shares outstanding and, if there is income from continuing operations during the period, the dilutive impact of share equivalents outstanding during the period. Reported Diluted (Loss) Income per Share from Continuing OperationsĪdjusted Income from Continuing OperationsĪdjusted Diluted Weighted Average Shares 1Īdjusted Diluted EPS from Continuing Operations Reported (Loss) Income from Continuing Operations We look forward to a strong finish to 2017 and we reaffirm the revenue and adjusted financial guidance we provided in August 2017." "Our core areas of focus, Sterile Injectables and Branded Specialty Products, are achieving impressive growth while we continue to drive margin expansion. "We continue to execute against our key priorities and deliver solid operating results," said Paul Campanelli, President and CEO of Endo. Adjusted EBITDA of $375 million compared to third-quarter 2016 adjusted EBITDA of $367 million.Adjusted diluted EPS from continuing operations of $0.91 compared to third-quarter 2016 adjusted diluted EPS from continuing operations of $1.01.Adjusted income from continuing operations of $204 million compared to third-quarter 2016 adjusted income from continuing operations of $226 million.Reported diluted loss per share from continuing operations of $0.45 compared to third-quarter 2016 reported diluted loss per share from continuing operations of $0.86.Reported net loss from continuing operations of $100 million compared to third-quarter 2016 reported net loss from continuing operations of $191 million.Revenues of $787 million, an 11 percent decrease compared to third-quarter 2016 revenues of $884 million.Company reaffirms full year 2017 revenues, adjusted diluted EPS and adjusted EBITDA financial guidance provided in August 2017Įndo International plc (NASDAQ: ENDP) today reported third-quarter 2017 financial results, including:.Third-quarter 2017 adjusted EBITDA of $375 million.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |